Skip to main content

RA/Inflammatory arthritis

RN.podcast.resized_34.jpg
Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.#1223  ALLN-346 a urate degrading enzyme in a pig model of goutL06 Emapalumab for treating MAS…
SJIA-associated ILD: Dr. Jonathan Hausmann Dr. Hausmann describes a new inflammatory lung disease at the 2019 ACR/ARP annual meeting in Atlanta.
Inflammatory Arthritis Persists After Immunotherapy Cessation: Dr. David Liew Dr. Liew discusses abstract #1808 Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Studies on the Changing Face of RA: Dr. Janet Pope Dr. Pope discusses abstract #171, #172 and #841 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Panel Presentation: Rheumatoid Arthritis Drs. Jack Cush, Arthur Kavanaugh and Jonathan Kay discuss several rheumatoid arthritis studies presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Abstracts discussed include abstract #1342, #1350, #1160, and more.
Safety of Methotrexate (The CIRT Trial): Dr. Jack Cush Dr. Cush discusses abstract #1890 on the CIRT trial as presented at the 2019 ACR/ARP annual meeting in Atlanta.
The Risk RA Prospective Study: Dr. Jonathan Kay Dr. Kay discusses abstract #1758 presented during a plenary session at the 2019 ACR/ARP annual meeting in Atlanta.
Antimalarials in RA: Dr. Janet Pope Dr. Janet Pope discusses two abstracts - #1891 and #896 - regarding hydroxychloroquine in RA at the 2019 ACR/ARP annual meeting in Atlanta.
Welcome to ACR 2019: Dr. Jack Cush Dr. Jack Cush gives an overview of RheumNow's 2019 ACR/ARP annual meeting coverage in Atlanta.
RN.podcast.resized_33.jpg
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.Study of ANA+ people without lupus or CTD shows that fatigue does not increase odds of having lupus or CTD. 1/3…
×